Roger Ulrich

Dr. Roger Ulrich is an entrepreneur and biotech executive with more than 30 years of operational and administrative experience in the pharmaceutical industry. He is a member of the Board of Directors for Acerta Pharma BV and served as the company’s Chief Scientific Officer until the majority acquisition by AstraZeneca in 2016. He is also on the Board of Directors for Remedy Pharmaceuticals, is a Senior Advisor to Frazier Healthcare Partners, and serves as a scientific advisor to several small pharma companies. Prior to Acerta, he was Founder and Chief Development Officer at Calistoga Pharmaceuticals Inc., where he led the development of CAL-101 (GS-1101, idelalisib) now approved as Zydelig® for the treatment of patients with hematologic malignancies. Calistoga was acquired by Gilead Sciences in 2011. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories/Rosetta Inpharmatics, Director of Regulatory Toxicology, Safety Pharmacology, Genetic Toxicology, Cellular and Molecular Toxicology, Microscopy and Microanalysis at Abbott Laboratories, and a Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Prior to his pharmaceutical industry career he held positions at West Virginia University, Michigan State University, and at Argonne National Laboratories. Dr. Ulrich holds several patents and has authored more than 125 publications. He received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.